These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20670943)

  • 1. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists.
    Liu SV; Schally AV; Hawes D; Xiong S; Fazli L; Gleave M; Cai J; Groshen S; Brands F; Engel J; Pinski J
    Clin Cancer Res; 2010 Sep; 16(18):4675-80. PubMed ID: 20670943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms.
    Schally AV; Redding TW; Comaru-Schally AM
    Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.
    Halmos G; Arencibia JM; Schally AV; Davis R; Bostwick DG
    J Urol; 2000 Feb; 163(2):623-9. PubMed ID: 10647698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
    Srkalovic G; Wittliff JL; Schally AV
    Cancer Res; 1990 Mar; 50(6):1841-6. PubMed ID: 2155060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
    Szepeshazi K; Schally AV; Halmos G
    Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [History of clinical studies on hypothalamic hormone analogs in Mexico].
    Schally AV; González Bárcena D
    Gac Med Mex; 2006; 142(4):315-25. PubMed ID: 17022307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
    Krebs LJ; Wang X; Pudavar HE; Bergey EJ; Schally AV; Nagy A; Prasad PN; Liebow C
    Cancer Res; 2000 Aug; 60(15):4194-9. PubMed ID: 10945629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers.
    Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
    Clin Cancer Res; 2001 Aug; 7(8):2340-3. PubMed ID: 11489810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.
    Issa MM; Lendvay TS; Bouet R; Young MR; Petros JA; Marshall FF
    J Urol; 2005 Sep; 174(3):893-7. PubMed ID: 16093982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypothalamic hormones and cancer.
    Schally AV; Comaru-Schally AM; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga JL; Halmos G
    Front Neuroendocrinol; 2001 Oct; 22(4):248-91. PubMed ID: 11587553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
    Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T; Redding TW; Ben-David M; Schally AV
    Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].
    Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Higashi Y; Negishi T
    Hinyokika Kiyo; 1995 Mar; 41(3):191-6. PubMed ID: 7741071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
    Koppán M; Nagy A; Schally AV; Plonowski A; Halmos G; Arencibia JM; Groot K
    Prostate; 1999 Feb; 38(2):151-8. PubMed ID: 9973101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.